Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01483664 · ClinicalTrials.gov registry record
Communication Skills Intervention to Promote Transition Into Survivorship
A clinical trial of Diffuse Large B Cell Lymphoma and Hodgkin's Lymphoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- 314
- Enrollment target
- 9
- Study locations
NCT01483664 is a study of Diffuse Large B Cell Lymphoma and Hodgkin's Lymphoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 314 participants, above the 216-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (45% higher). The trial reports 9 study locations across 4 states.
The verdict
NCT01483664, a study of Diffuse Large B Cell Lymphoma and Hodgkin's Lymphoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- 314 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study is to improve the communication skills of physicians who transition lymphoma cancer patients from the end of treatment to survivorship.
Conditions Studied
Study Locations (9)
New York
- Maimonides Medical Center - Brooklyn
- Memorial Sloan Kettering Cancer Center at Commack - Commack
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Cancer Center at Mercy - Rockville Centre
- Memorial Sloan Kettering Cancer Center at Phelps - Sleepy Hollow
Florida
- Tampa General Hospital - Tampa
- Moffitt Cancer Center - Tampa
New Jersey
- Memorial Sloan Kettering at Basking Ridge - Basking Ridge
Texas
- Md Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 314 participants |
| Start Date | 2011-11 |
| Est. Completion | 2026-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01483664
The ClinicalTrials.gov registry entry for NCT01483664 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 314 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 216-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (45% higher). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 0 interventions.
NCT01483664 reports 9 study locations spanning 4 distinct geographic areas - top geographies include New York, Florida, New Jersey.
Frequently Asked Questions
What is clinical trial NCT01483664 about?
NCT01483664 is a clinical study titled "Communication Skills Intervention to Promote Transition Into Survivorship". The purpose of this study is to improve the communication skills of physicians who transition lymphoma cancer patients from the end of treatment to survivorship.
What is the current status of trial NCT01483664?
This trial is currently active not recruiting. The enrollment target is 314 participants. The study started on 2011-11. Estimated completion is 2026-11.
What conditions does trial NCT01483664 study?
This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma, Hodgkin's Lymphoma.
Who is sponsoring clinical trial NCT01483664?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01483664 being conducted?
This trial has 9 study locations across Florida, New Jersey, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diffuse Large B Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Non-interventional, International, Multicentre Clinical Research Study to Build the Largest Collection of Multimodal Data (Including Clinical Data, Imaging Data and Omics Data) in Oncology
RECRUITING
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
RECRUITING · Phase 2
-
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
RECRUITING · Phase 1
-
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.